- Category: Experimental HCV Drugs
- Published on Friday, 17 April 2015 00:00
- Written by NIH
The over-the-counter allergy medication chlorcyclizine HCl, or CCZ, was found to be a potent inhibitor of hepatitis C virus (HCV) genotype 1b and 2a replication, according to a laboratory study described in the April 8 edition of Science Translational Medicine. The study authors suggest that this older drug could potentially be an affordable component of combination treatment. A Phase 1 clinical trial is now underway.